Details of the Drug

General Information of Drug (ID: DM6L4H2)

Drug Name
Cobicistat
Synonyms
1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 776
Topological Polar Surface Area (xlogp) 5.7
Rotatable Bond Count (rotbonds) 20
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 4 hours [4]
Metabolism
The drug is metabolized via the CYP3A and to a minor extent by CYP2D6 enzymes and does not undergo glucuronidation [5]
Chemical Identifiers
Formula
C40H53N7O5S2
IUPAC Name
1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
Canonical SMILES
CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
InChI
InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1
InChIKey
ZCIGNRJZKPOIKD-CQXVEOKZSA-N
Cross-matching ID
PubChem CID
25151504
ChEBI ID
CHEBI:72291
CAS Number
1004316-88-4
DrugBank ID
DB09065
TTD ID
D02VJP
INTEDE ID
DR0364
ACDINA ID
D00146

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytochrome P450 3A (CYP3A) TTIJQ3O NOUNIPROTAC Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 3A7 (CYP3A7)
Main DME 		DERD86B CP3A7_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cobicistat
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Cobicistat caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Fostemsavir DM50ILT Moderate Decreased metabolism of Cobicistat caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Coadministration of a Drug Treating the Disease Different from Cobicistat (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Decreased metabolism of Cobicistat caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [41]
Arn-509 DMT81LZ Major Increased metabolism of Cobicistat caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [42]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Cobicistat caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [43]
Oliceridine DM6MDCF Major Decreased metabolism of Cobicistat caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [44]
Ivabradine DM0L594 Major Decreased metabolism of Cobicistat caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [42]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Cobicistat caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [42]
Erdafitinib DMI782S Major Decreased metabolism of Cobicistat caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [45]
Pexidartinib DMS2J0Z Moderate Decreased metabolism of Cobicistat caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [46]
Talazoparib DM1KS78 Moderate Decreased clearance of Cobicistat due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [47]
HKI-272 DM6QOVN Major Decreased metabolism of Cobicistat caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
LY2835219 DM93VBZ Major Decreased metabolism of Cobicistat caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Tucatinib DMBESUA Moderate Decreased metabolism of Cobicistat caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
Palbociclib DMD7L94 Major Decreased metabolism of Cobicistat caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
PF-04449913 DMSB068 Major Decreased metabolism of Cobicistat caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [52]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Cobicistat caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [53]
Revefenacin DMMP5SI Moderate Decreased clearance of Cobicistat due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [54]
Intedanib DMSTA36 Moderate Decreased clearance of Cobicistat due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [55]
Osilodrostat DMIJC9X Major Decreased metabolism of Cobicistat caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [47]
OPC-34712 DMHG57U Major Decreased metabolism of Cobicistat caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [56]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Cobicistat caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [57]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Cobicistat and Ingrezza. Dystonic disorder [8A02] [58]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Cobicistat caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Cobicistat caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [60]
Tazemetostat DMWP1BH Major Decreased metabolism of Cobicistat caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [61]
Ripretinib DM958QB Major Decreased metabolism of Cobicistat caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [42]
Avapritinib DMK2GZX Major Decreased metabolism of Cobicistat caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [47]
Daclatasvir DMSFK9V Major Decreased metabolism of Cobicistat caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [47]
GS-9857 DMYU6P5 Moderate Decreased clearance of Cobicistat due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [62]
Levamlodipine DM92S6N Moderate Decreased metabolism of Cobicistat caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [59]
TP-434 DM5A31S Minor Decreased metabolism of Cobicistat caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [63]
Berotralstat DMWA2DZ Major Decreased clearance of Cobicistat due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [64]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Cobicistat caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [65]
Eluxadoline DMYZ0P1 Major Decreased clearance of Cobicistat due to the transporter inhibition by Eluxadoline. Irritable bowel syndrome [DD91] [47]
Pemigatinib DM819JF Major Decreased metabolism of Cobicistat caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [47]
Brigatinib DM7W94S Major Decreased metabolism of Cobicistat caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [66]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Cobicistat caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
PF-06463922 DMKM7EW Major Decreased metabolism of Cobicistat caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [68]
Osimertinib DMRJLAT Major Decreased metabolism of Cobicistat caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [69]
Pralsetinib DMWU0I2 Major Decreased metabolism of Cobicistat caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [70]
Capmatinib DMYCXKL Major Decreased metabolism of Cobicistat caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [71]
Selpercatinib DMZR15V Major Decreased metabolism of Cobicistat caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
Artesunate DMR27C8 Moderate Decreased clearance of Cobicistat due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [46]
GDC-0199 DMH0QKA Major Decreased metabolism of Cobicistat caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [72]
IPI-145 DMWA24P Major Decreased metabolism of Cobicistat caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [73]
LGX818 DMNQXV8 Major Decreased metabolism of Cobicistat caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [74]
Ubrogepant DM749I3 Major Decreased metabolism of Cobicistat caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [75]
Rimegepant DMHOAUG Moderate Decreased metabolism of Cobicistat caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [76]
Siponimod DM2R86O Major Decreased metabolism of Cobicistat caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [42]
Deflazacort DMV0RNS Major Decreased metabolism of Cobicistat caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [47]
Fedratinib DM4ZBK6 Major Decreased metabolism of Cobicistat caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Entrectinib DMMPTLH Major Decreased metabolism of Cobicistat caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [42]
S-297995 DM26IH8 Moderate Decreased metabolism of Cobicistat caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [47]
Olaparib DM8QB1D Major Decreased metabolism of Cobicistat caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [42]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Cobicistat caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [77]
Istradefylline DM20VSK Major Decreased metabolism of Cobicistat caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [78]
Abametapir DM2RX0I Moderate Decreased metabolism of Cobicistat caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [79]
Lefamulin DME6G97 Major Decreased clearance of Cobicistat due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [80]
Relugolix DMK7IWL Major Decreased clearance of Cobicistat due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [81]
Darolutamide DMV7YFT Moderate Decreased metabolism of Cobicistat caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [82]
Upadacitinib DM32B5U Major Decreased metabolism of Cobicistat caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [83]
Voxelotor DMCS6M5 Major Decreased metabolism of Cobicistat caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [84]
LDE225 DMM9F25 Major Decreased metabolism of Cobicistat caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [85]
Larotrectinib DM26CQR Major Decreased metabolism of Cobicistat caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
LEE011 DMMX75K Major Decreased metabolism of Cobicistat caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Cobicistat caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [47]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Cobicistat due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [46]
As-1670542 DMV05SW Moderate Decreased metabolism of Cobicistat caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [47]
Elagolix DMB2C0E Major Decreased metabolism of Cobicistat caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [86]
Fluticasone DMGCSVF Major Decreased metabolism of Cobicistat caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [87]
Betrixaban DM2C4RF Moderate Decreased clearance of Cobicistat due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [88]
⏷ Show the Full List of 70 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cobicistat 150 mg tablet 150 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535).
2 Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206.
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017 Apr 24;31(7):917-952.
7 Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
8 Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
19 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
20 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
21 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
22 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
23 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
24 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
25 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
26 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
27 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
28 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
29 Drug Interactions Flockhart Table
30 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
31 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
32 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
33 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
34 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
35 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
36 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
38 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
39 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
40 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
41 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
42 Cerner Multum, Inc. "Australian Product Information.".
43 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
44 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
45 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
46 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
47 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
49 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
50 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
51 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
52 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
53 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
54 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
55 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
56 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
57 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
58 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
59 Canadian Pharmacists Association.
60 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
61 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
62 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
63 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
64 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
65 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
66 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
67 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
68 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
71 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
72 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
73 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
74 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
75 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
76 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
77 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
78 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
79 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
80 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
81 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
82 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
83 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
84 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
85 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
87 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
88 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.